NEET PG Antimicrobial Pharmacology Glossary 2026: High-Yield Drug Classes, Mechanisms of Action and MCQ Mnemonics

You are probably staring at another antimicrobial classification table, wondering how you'll memorize 47 different drug names, their mechanisms, and spectrum patterns before NEET PG. Here's the thing: antimicrobial pharmacology makes up 12-15% of the pharmacology section, and it's tested differently than you think.

NEET PG doesnt just ask "What's the mechanism of penicillin?" They ask scenario-based questions: "A 28-year-old presents with pneumonia. Sputum culture shows penicillin-resistant Streptococcus pneumoniae. Which drug would you choose?" The difference between scoring 65% and 85% in pharmacology lies in pattern recognition, not rote memorization.

This glossary organizes antimicrobials the way NEET PG tests them — by clinical scenarios, resistance patterns, and high-yield associations. Every entry includes the mechanism, spectrum, key adverse effects, and a memory hook thats actually useful during the exam.

Core Antimicrobial Mechanisms of Action

Before diving into specific drugs, master these 5 fundamental mechanisms. Every antimicrobial question ultimately traces back to one of these pathways.

1. Cell Wall Synthesis Inhibition

Target: Peptidoglycan cross-linking in bacterial cell wall Drug Classes: Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams), vancomycin, bacitracin Clinical Pearl: Most bactericidal against actively dividing organisms NEET PG Trap: Ineffective against mycoplasma (no cell wall) and in stationary-phase infections

2. Protein Synthesis Inhibition

30S Ribosomal Subunit: Aminoglycosides, tetracyclines 50S Ribosomal Subunit: Chloramphenicol, macrolides, lincosamides Clinical Pearl: 30S inhibitors are typically bactericidal; 50S inhibitors are bacteriostatic Memory Hook: "30 kills (cidal), 50 stops (static)" — though watch for exceptions like chloramphenicol

3. DNA/RNA Synthesis Inhibition

DNA Gyrase/Topoisomerase: Fluoroquinolones RNA Polymerase: Rifampin DNA Synthesis: Metronidazole (anaerobes) NEET PG Favorite: Fluoroquinolone resistance mechanisms and tendon rupture risk

4. Cell Membrane Disruption

Mechanism: Direct membrane damage Examples: Polymyxins (colistin), daptomycin, antifungals (amphotericin B, azoles) Clinical Use: Often reserved for multidrug-resistant organisms Key Point: Nephrotoxicity is common due to membrane effects on kidney cells

5. Metabolic Pathway Inhibition

Folate Synthesis: Sulfonamides, trimethoprim Mycolic Acid Synthesis: Isoniazid, ethambutol (mycobacteria) Ergosterol Synthesis: Antifungals (azoles, allylamines)

Beta-Lactam Antibiotics: The NEET PG Workhorses

Beta-lactams remain the most tested antimicrobial class. Master the resistance patterns and clinical applications for each subgroup.

Penicillins

Natural Penicillins (Penicillin G/V)

• Spectrum: Gram-positive cocci, anaerobes (except Bacteroides)

• Clinical Use: Streptococcal infections, syphilis, gas gangrene

• Resistance: Beta-lactamase production

• NEET PG Pearl: Still first-line for Group A strep pharyngitis

Anti-Staphylococcal Penicillins (Methicillin, Nafcillin)

• Key Feature: Beta-lactamase resistant

• Limitation: Ineffective against MRSA (altered PBP2a)

• Clinical Use: MSSA infections

• Memory Hook: "Naf kills Staph, but not MRSA"

Aminopenicillins (Ampicillin, Amoxicillin)

• Extended Spectrum: Adds some gram-negatives (E. coli, Proteus)

• Clinical Use: UTI, respiratory tract infections, Listeria meningitis

• Side Effect: Ampicillin rash with EBV

• Combination: Amoxicillin + clavulanate extends to beta-lactamase producers

Anti-Pseudomonal Penicillins (Piperacillin)

• Spectrum: Broadest penicillin spectrum including Pseudomonas

• Clinical Use: Hospital-acquired infections, neutropenic fever

• Combination: Piperacillin-tazobactam (Zosyn) — covers most hospital pathogens

• NEET PG High-Yield: Know when to use pip-tazo vs carbapenems

For deeper understanding of beta-lactam mechanisms and resistance patterns, explore our beta-lactam antibiotics lessons and practice with targeted MCQs.

Cephalosporins by Generation

First Generation (Cefazolin, Cephalexin)

• Spectrum: Gram-positive cocci, some gram-negatives

• Clinical Use: Skin/soft tissue infections, surgical prophylaxis

• Memory: "First gen = First choice for skin"

Second Generation (Cefuroxime, Cefoxitin)

• Added Coverage: H. influenzae, Moraxella, anaerobes (cefoxitin)

• Clinical Use: Respiratory tract infections, mixed infections

• NEET PG Favorite: Cefoxitin for Bacteroides coverage

Third Generation (Ceftriaxone, Ceftazidime)

• Spectrum: Excellent gram-negative coverage, reduced gram-positive

• Clinical Use: Meningitis (ceftriaxone), Pseudomonas (ceftazidime)

• Key Difference: Ceftazidime covers Pseudomonas; ceftriaxone doesnt

• Side Effects: Biliary sludge (ceftriaxone), bleeding (cefoperazone)

Fourth Generation (Cefepime)

• Spectrum: Combines 3rd gen gram-negative with better gram-positive

• Clinical Use: Hospital-acquired pneumonia, neutropenic fever

• Advantage: More stable against beta-lactamases

Fifth Generation (Ceftaroline)

• Unique Feature: MRSA coverage

• Mechanism: Binds to PBP2a

• Clinical Use: Complicated skin infections, pneumonia

When working through cephalosporin classification questions, try using Oncourse flashcards for spaced repetition of generation-specific spectrums.

Carbapenems and Monobactams

Carbapenems (Imipenem, Meropenem, Ertapenem)

• Spectrum: Broadest beta-lactam spectrum

• Clinical Use: Serious gram-negative infections, empiric therapy for sepsis

• Resistance: Carbapenemases (NDM, KPC, OXA)

• Side Effects: Seizures (imipenem > meropenem), C. diff

• NEET PG Pearl: Ertapenem doesnt cover Pseudomonas or Acinetobacter

Monobactams (Aztreonam)

• Unique Feature: Only beta-lactam safe in penicillin allergy

• Spectrum: Gram-negative only (no gram-positive or anaerobic activity)

• Clinical Use: Gram-negative infections in penicillin-allergic patients

• Memory Hook: "AZT = Anti-Zero (gram-positive), Totally safe (in allergy)"

Protein Synthesis Inhibitors

Aminoglycosides

Examples: Gentamicin, amikacin, tobramycin, streptomycin Mechanism: 30S ribosomal subunit binding, bactericidal Spectrum: Gram-negative aerobes, synergy with cell wall inhibitors Clinical Uses:

• Serious gram-negative infections

• Endocarditis (with beta-lactams)

• Tuberculosis (streptomycin)

Toxicities:

• Nephrotoxicity: Dose-dependent, reversible

• Ototoxicity: Vestibular (streptomycin) vs cochlear (gentamicin)

• Neuromuscular blockade: Especially post-anesthesia

NEET PG High-Yield: Once-daily dosing reduces toxicity while maintaining efficacy due to concentration-dependent killing and post-antibiotic effect. Resistance Mechanisms:

1. Enzymatic modification (most common)

2. Altered ribosomal binding

3. Reduced uptake

Tetracyclines

Examples: Tetracycline, doxycycline, minocycline, tigecycline Mechanism: 30S ribosomal subunit, bacteriostatic Spectrum: Broad-spectrum including atypicals, rickettsiae, spirochetes Clinical Applications:

• Doxycycline: Malaria prophylaxis, rickettsial diseases, atypical pneumonia

• Minocycline: MRSA skin infections

• Tigecycline: Multi-drug resistant gram-positives and gram-negatives

Contraindications: Pregnancy, children under 8 (teeth staining) Side Effects: GI upset, photosensitivity, pseudotumor cerebri

The mnemonic "VACUUM PACKED" helps remember tetracycline coverage: Vibrio, Atypicals, Chlamydia, Ureaplasma, Ureaplasma, Mycoplasma, Pasteurella, Anaerobes (some), Chlamydia, Klebsiella, Ehrlichia, Dermatophytes. Rezzy AI can help create personalized mnemonics based on your specific weak areas.

Macrolides and Related

Macrolides (Erythromycin, Clarithromycin, Azithromycin) Mechanism: 50S ribosomal subunit, bacteriostatic Spectrum: Gram-positives, atypicals, some gram-negatives Clinical Pearls:

• Azithromycin: Longest half-life, better gram-negative coverage

• Clarithromycin: H. pylori eradication, MAC prophylaxis

• Erythromycin: GI motility agent, most GI side effects

Drug Interactions: CYP3A4 inhibition (except azithromycin) Cardiac Risk: QT prolongation, especially with azithromycin Clindamycin

• Spectrum: Gram-positives, anaerobes (including Bacteroides)

• Clinical Use: Anaerobic infections, severe strep/staph skin infections

• Major Risk: C. difficile colitis

• Mechanism: 50S ribosomal subunit (lincosamide)

DNA/RNA Synthesis Inhibitors

Fluoroquinolones

Mechanism: DNA gyrase (gram-negatives) and topoisomerase IV (gram-positives) inhibition Classification by Generations: Second Generation (Ciprofloxacin, Ofloxacin)

• Spectrum: Excellent gram-negative including Pseudomonas

• Clinical Use: UTI, GI infections, anthrax

• Limitation: Poor gram-positive and anaerobic coverage

Third Generation (Levofloxacin)

• Added Coverage: Streptococcus pneumoniae, atypicals

• Clinical Use: Community-acquired pneumonia, sinusitis

• Advantage: Once-daily dosing

Fourth Generation (Moxifloxacin)

• Spectrum: Broadest including anaerobes

• Clinical Use: Complicated pneumonia, complicated skin infections

• Unique: No renal adjustment needed

Resistance Mechanisms:

1. Target enzyme mutations

2. Efflux pumps

3. Plasmid-mediated resistance

Toxicities:

• Tendon rupture: Especially Achilles, increased with steroids/age

• CNS effects: Seizures, psychosis

• Cardiac: QT prolongation

• Glucose: Hypo/hyperglycemia

NEET PG Pearl: Avoid in pregnancy, children, and myasthenia gravis.

Other DNA/RNA Inhibitors

Metronidazole

• Mechanism: Reduction to toxic metabolites disrupting DNA

• Spectrum: Anaerobes (including Bacteroides), protozoa

• Clinical Use: C. difficile, anaerobic infections, H. pylori

• Side Effects: Disulfiram-like reaction with alcohol, peripheral neuropathy

Rifampin

• Mechanism: RNA polymerase inhibition

• Clinical Use: Tuberculosis, MRSA (combination therapy), meningococcal prophylaxis

• Drug Interactions: Powerful CYP inducer

• Side Effect: Orange discoloration of body fluids

Glycopeptides and Lipopeptides

Vancomycin

Mechanism: Binds D-ala-D-ala peptide, preventing peptidoglycan cross-linking Spectrum: Gram-positive only, including MRSA Clinical Uses:

• MRSA infections

• C. difficile colitis (oral)

• Endocarditis in penicillin-allergic patients

Toxicities:

• Red man syndrome: Histamine release from rapid infusion

• Nephrotoxicity: Especially with aminoglycosides

• Ototoxicity: High trough levels

Resistance: VRE (vancomycin-resistant enterococci) — target becomes D-ala-D-lac

Newer Agents

Linezolid

• Mechanism: 50S ribosomal subunit (unique binding site)

• Spectrum: Gram-positives including VRE

• Advantages: Oral bioavailability, tissue penetration

• Toxicities: Thrombocytopenia, peripheral neuropathy, serotonin syndrome

Daptomycin

• Mechanism: Cell membrane depolarization

• Clinical Use: Complicated skin infections, bacteremia, endocarditis

• Limitation: Inactivated by pulmonary surfactant

• Side Effect: CK elevation, myopathy

Antimycobacterial Agents

Understanding TB drug combinations and resistance patterns is crucial for NEET PG internal medicine questions.

First-Line Anti-TB Drugs

Isoniazid (INH)

• Mechanism: Inhibits mycolic acid synthesis

• Resistance: KatG gene mutations

• Toxicity: Peripheral neuropathy (give B6), hepatitis

• Monitoring: LFTs, especially in elderly/alcoholics

Rifampin (RMP)

• Mechanism: RNA polymerase inhibition

• Resistance: rpoB gene mutations

• Toxicity: Hepatitis, orange discoloration

• Drug Interactions: CYP inducer

Ethambutol (EMB)

• Mechanism: Inhibits arabinosyl transferase

• Toxicity: Optic neuropathy (dose-related)

• Monitoring: Monthly visual acuity and color discrimination

• Contraindication: Children under 5 (cant assess vision)

Pyrazinamide (PZA)

• Mechanism: Unknown (requires acidic pH)

• Toxicity: Hepatitis, hyperuricemia

• Limitation: Inactive against M. bovis

Standard Regimen: HRZE × 2 months, then HR × 4 months (total 6 months)

Second-Line Anti-TB Drugs

Used for drug-resistant TB or when first-line drugs cant be used:

Injectable Agents: Amikacin, capreomycin, streptomycin Fluoroquinolones: Levofloxacin, moxifloxacin Other Oral Agents: Ethionamide, cycloserine, PAS MDR-TB Definition: Resistance to at least INH + RMP XDR-TB Definition: MDR + resistance to fluoroquinolone + second-line injectable

Practice antimycobacterial scenarios with our antimycobacterial drugs MCQs to master resistance pattern recognition.

Antifungal Agents

Polyenes

Amphotericin B

• Mechanism: Binds ergosterol, creates membrane pores

• Spectrum: Broadest antifungal spectrum

• Clinical Use: Serious systemic mycoses, empiric antifungal therapy

• Formulations: Conventional (nephrotoxic) vs lipid formulations (less toxic)

• Side Effects: Nephrotoxicity, infusion reactions, hypokalemia

Azoles

Mechanism: Inhibit 14α-demethylase (ergosterol synthesis) Fluconazole

• Spectrum: Candida (except C. krusei), Cryptococcus

• Clinical Use: Candidemia, cryptococcal meningitis, prophylaxis

• Advantages: Oral/IV, good CNS penetration

• Limitation: No activity against Aspergillus

Itraconazole

• Spectrum: Broader including Aspergillus, endemic mycoses

• Clinical Use: Histoplasmosis, blastomycosis, aspergillosis

• Limitation: Poor oral absorption, drug interactions

Voriconazole

• Spectrum: Aspergillus, Candida, emerging molds

• Clinical Use: First-line for invasive aspergillosis

• Side Effects: Visual disturbances, hepatitis, photosensitivity

Posaconazole

• Spectrum: Broadest azole including mucormycosis

• Clinical Use: Prophylaxis in high-risk patients, salvage therapy

• Advantage: Once-daily dosing

Echinocandins

Examples: Caspofungin, micafungin, anidulafungin Mechanism: Inhibit β-glucan synthesis in fungal cell wall Spectrum: Candida, Aspergillus (not active against Cryptococcus) Clinical Use: Candidemia, invasive aspergillosis Advantage: Fungicidal against Candida, minimal drug interactions

Antiviral Agents

Anti-Herpes Drugs

Acyclovir

• Mechanism: Guanosine analog, terminates DNA synthesis

• Activation: Requires viral thymidine kinase

• Clinical Use: HSV, VZV infections

• Resistance: Thymidine kinase mutations

Valacyclovir: Oral prodrug of acyclovir, better bioavailability Ganciclovir

• Spectrum: CMV, HSV, VZV

• Clinical Use: CMV retinitis, CMV prophylaxis in transplant

• Toxicity: Bone marrow suppression

Anti-Influenza Drugs

Oseltamivir (Tamiflu)

• Mechanism: Neuraminidase inhibitor

• Clinical Use: Influenza A and B treatment/prophylaxis

• Timing: Most effective within 48 hours of symptom onset

• Side Effects: Nausea, psychiatric symptoms (rare)

Zanamivir: Inhaled neuraminidase inhibitor

Anti-HIV Drugs

Nucleoside RTIs (NRTIs)

• Examples: Zidovudine (AZT), lamivudine, emtricitabine

• Mechanism: DNA chain termination

• Side Effects: Mitochondrial toxicity, lactic acidosis

Non-Nucleoside RTIs (NNRTIs)

• Examples: Efavirenz, rilpivirine

• Mechanism: Allosteric RT inhibition

• Resistance: Single point mutations

Protease Inhibitors

• Examples: Atazanavir, darunavir

• Mechanism: Prevent viral protein maturation

• Side Effects: GI intolerance, metabolic syndrome

Integrase Inhibitors

• Examples: Raltegravir, dolutegravir

• Mechanism: Block viral DNA integration

• Advantages: High barrier to resistance, fewer interactions

For comprehensive antiviral drug coverage, review our antiviral drugs lessons and test your knowledge with antiviral MCQs.

High-Yield Antimicrobial Resistance Patterns

MRSA (Methicillin-Resistant Staphylococcus aureus)

Mechanism: mecA gene produces altered PBP2a Treatment Options: Vancomycin, linezolid, daptomycin, ceftaroline Clinical Impact: Hospital-acquired vs community-acquired strains have different virulence

ESBL (Extended-Spectrum Beta-Lactamase)

Organisms: E. coli, Klebsiella Resistance Pattern: Resistant to penicillins, cephalosporins; sensitive to carbapenems Treatment: Carbapenems are preferred NEET PG Pearl: ESBL producers often co-resistant to fluoroquinolones

Carbapenem-Resistant Enterobacteriaceae (CRE)

Mechanisms: Carbapenemases (KPC, NDM, OXA), efflux pumps Treatment: Colistin, tigecycline (limited options) Clinical Significance: Pan-resistant organisms, high mortality

Vancomycin-Resistant Enterococci (VRE)

Mechanism: Van genes change target from D-ala-D-ala to D-ala-D-lac Treatment: Linezolid, daptomycin Prevention: Contact precautions, antimicrobial stewardship

Clinical Scenarios and Drug Selection

Community-Acquired Pneumonia

Typical Pathogens: S. pneumoniae, H. influenzae First Choice: Amoxicillin or macrolide (outpatient) Severe/Hospitalized: Beta-lactam + macrolide or respiratory fluoroquinolone

Healthcare-Associated Pneumonia

Risk Factors: Recent hospitalization, nursing home, immunocompromised Coverage Needed: MRSA, Pseudomonas Empiric Therapy: Pip-tazo or carbapenem + vancomycin or linezolid

Urinary Tract Infections

Uncomplicated Cystitis: Nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin Complicated UTI: Fluoroquinolone or beta-lactam based on culture Catheter-Associated: Remove catheter + targeted therapy

Skin and Soft Tissue Infections

Cellulitis: Cephalexin (outpatient), clindamycin (MRSA risk) Necrotizing Fasciitis: Clindamycin + penicillin (Group A strep) Diabetic Foot: Broad-spectrum with anaerobic coverage

Understanding these clinical patterns helps answer NEET PG questions that test application rather than just memorization. The Synapses game can help reinforce these clinical associations through spaced repetition.

MCQ Memory Techniques

Drug Name Associations

Penicillin Generations:

• "Natural Pen" = Natural penicillins (G, V)

• "Amino Pen" = Aminopenicillins (ampicillin, amoxicillin)

• "Anti-Staph" = Methicillin, nafcillin

• "Anti-Pseudo" = Piperacillin

Cephalosporin Memory:

• 1st Gen: "CEF-azolin" (surgical prophylaxis)

• 2nd Gen: "CEF-uroxime" (respiratory)

• 3rd Gen: "CEF-triaxone" (meningitis), "CEF-tazidime" (Pseudomonas)

• 4th Gen: "CEF-epime" (hospital bugs)

Fluoroquinolone Spectrum:

• "CIPRO" = Pseudomonas coverage

• "LEVO" = Lung bugs (pneumonia)

• "MOXI" = Most coverage (anaerobes too)

Toxicity Mnemonics

Aminoglycoside Toxicity: "Gentamicin Gives Nephritis, Ototoxicity, Neuromuscular blockade" Chloramphenicol: "Gray Baby Syndrome, Aplastic Anemia, Bone marrow suppression" Vancomycin: "Red Man syndrome, Renal toxicity, 'Ringing' (ototoxicity)"

Resistance Patterns

MRSA Treatment: "VLCD" = Vancomycin, Linezolid, Ceftaroline, Daptomycin Carbapenem Resistance: "KND-OXA" = KPC, NDM, OXA carbapenemases

Frequently Asked Questions

What percentage of NEET PG pharmacology questions focus on antimicrobials?

Antimicrobial pharmacology typically comprises 35-40% of the pharmacology section in NEET PG. This translates to approximately 12-15 questions out of the total pharmacology allocation. The questions often integrate clinical scenarios with drug selection, making pure memorization insufficient.

Which antimicrobial topics are most frequently tested in NEET PG 2026?

Based on recent patterns, beta-lactam antibiotics (especially cephalosporin generations and resistance mechanisms), fluoroquinolone classifications, antimycobacterial therapy for TB, and antifungal drug selection appear most frequently. Clinical scenario-based questions testing appropriate empiric therapy are increasingly common.

How should I approach antimicrobial resistance questions in NEET PG?

Focus on understanding mechanisms rather than memorizing organism lists. Key patterns include: MRSA (altered PBP), ESBL (extended beta-lactamase), carbapenem resistance (carbapenemases), and VRE (altered target). Know the first-line treatments for each resistant pattern.

What's the best way to remember antimicrobial drug classifications?

Use systematic approaches: group by mechanism first, then by spectrum. For beta-lactams, master the "generations" concept. For other classes, focus on unique features (aminoglycosides = ototoxicity, fluoroquinolones = tendon rupture). Clinical associations work better than pure lists.

Which antimicrobial side effects are high-yield for NEET PG MCQs?

Major toxicities tested include: aminoglycoside ototoxicity/nephrotoxicity, fluoroquinolone tendon rupture, vancomycin red man syndrome, chloramphenicol gray baby syndrome, and tetracycline teeth staining. Know both the toxicity and the population at risk.

How important are antiviral and antifungal drugs for NEET PG?

While bacterial antimicrobials dominate, antiviral therapy (especially anti-HIV combinations and oseltamivir) and antifungal drugs (azole mechanisms and amphotericin toxicity) appear regularly. They're often tested in clinical context - HIV treatment failure, candidemia management, or influenza prophylaxis scenarios.

Prepare smarter with Oncourse AI — adaptive MCQs, spaced repetition, and AI explanations built for NEET PG. Download free on Android and iOS.